Trials / Completed
CompletedNCT05569941
A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects
A Phase 1, Blinded, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics of Single and Multiple Ascending Doses of ABI-4334 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Assembly Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess safety, tolerability, and PK of single ascending doses (SAD) of ABI-4334 in Part A and multiple-ascending doses (MAD) of ABI-4334 in Part B in healthy subjects. Effect of food will also be evaluated in Part A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-4334 Tablet | ABI-4334 Tablet |
| DRUG | ABI-4334 Placebo | Placebo to ABI-4334 Tablet |
Timeline
- Start date
- 2022-11-11
- Primary completion
- 2023-04-12
- Completion
- 2023-04-12
- First posted
- 2022-10-06
- Last updated
- 2023-09-13
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT05569941. Inclusion in this directory is not an endorsement.